Clinical trials: Adolescent Behaviors
Psychological Well-Being, Adolescent Behavior
World Digital Detox Program for Enhancing Youth and Family Well-being
The pervasive presence of digital devices and technology has reshaped contemporary society, providing numerous benefits but also prompting concerns about prolonged screen time, particularly with smartphones and social media.
- Conditions
- Psychological Well-Being, Adolescent Behavior, Family
- Trial name
- NCT06154681
- Testing
- World Digital Detox Family Program
- Where
- India
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Innowage Limited
ADHD
Efficacy and Safety of SPD503 in Combination With Psychostimulants
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal…
- Trial name
- NCT00734578
- Testing
- SPD503-AM, SPD503-PM
- Where
- 61 sites in United States
- Volunteers
- 461 people
- Sponsor
- Shire
Depression, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00619619
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Attention Deficit Disorder With Hyperactivity
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study aims to assess the effectiveness of atomoxetine on psychosocial functioning and emotional well being of children and adolescents with ADHD and to evaluate whether and in what measure the presence of comorbid conditions…
- Trial name
- NCT00320528
- Testing
- atomoxetine
- Where
- 20 sites in Italy
- Volunteers
- 269 people
- Sponsor
- Eli Lilly and Company
Bronchospasm, Activity/Exercise Induced Bronchospasm
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test…
- Trial name
- NCT00118716
- Testing
- Fluticasone propionate/salmeterol, Fluticasone Propionate
- Where
- 50 sites in United States
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Major Depressive Disorder
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of…
- Trial name
- NCT00531947
- Testing
- Selegiline Transdermal System
- Where
- 20 sites in United States
- Volunteers
- 308 people
- Sponsor
- Somerset Pharmaceuticals
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552915
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 79 sites in United States
- Volunteers
- 464 people
- Sponsor
- Shire
ADHD
Adult Normative Performance of the Quotient ADHD System
This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System…
- Trial name
- ADHD (NCT01308450)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- BioBehavioral Diagnostics Company
Attention Deficit Disorder With Hyperactivity
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by…
- Trial name
- NCT00758160
- Testing
- OROS Methylphenidate
- Volunteers
- 296 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
ADHD
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an…
- Trial name
- NCT00228540
- Testing
- Modafinil
- Where
- 39 sites in United States
- Sponsor
- Cephalon